Stablepharma Secures €2.5M EIC Grant, Among Top 71 EU Innovators

Stablepharma Secures €2.5M EIC Grant, Among Top 71 EU Innovators UK biotech Stablepharma Ltd has secured a €2.5M grant from the European Innovation Council (EIC) Accelerator Programme. The funding acknowledges its innovative refrigeration-free pharmaceutical technology, meeting the EIC’s high standards…

Read MoreStablepharma Secures €2.5M EIC Grant, Among Top 71 EU Innovators

Stablepharma Wins €2.5M EIC Accelerator Grant, Named Among Europe’s Top 71 Innovators

Stablepharma Secures €2.5M EIC Grant, Named Top EU Innovator UK-based biotechnology firm Stablepharma Ltd has been awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program. The grant recognises the company’s cutting-edge fridge-free pharmaceutical technology, which meets EIC’s…

Read MoreStablepharma Wins €2.5M EIC Accelerator Grant, Named Among Europe’s Top 71 Innovators

Precision BioSciences Reports Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences Announces Early Safety and Antiviral Results for PBGENE-HBV in ELIMINATE-B Trial Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,…

Read MorePrecision BioSciences Reports Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Reverb Therapeutics Raises $12M Seed Funding to Advance Amplify•R™ Cytokine Signaling Platform

Reverb Therapeutics Secures $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, announced it has closed a USD $12 Million financing led by founding investor Amplitude Ventures. Other…

Read MoreReverb Therapeutics Raises $12M Seed Funding to Advance Amplify•R™ Cytokine Signaling Platform

ClearNote Health’s Avantect® Pancreatic Cancer Test Approved in New York

ClearNote Health’s Avantect® Pancreatic Cancer Test Approved in New York ClearNote Health has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) for its Avantect® Pancreatic Cancer Test. This approval allows New York clinicians…

Read MoreClearNote Health’s Avantect® Pancreatic Cancer Test Approved in New York

Arcus Biosciences Retains Casdatifan Rights and Announces $150M Stock Offering

Arcus Biosciences Retains Casdatifan Rights and Announces $150M Stock Offering Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage global biopharmaceutical company specializing in cancer treatments, announced today that Gilead’s exclusive option rights to its potential best-in-class HIF-2α inhibitor, casdatifan, have expired. In…

Read MoreArcus Biosciences Retains Casdatifan Rights and Announces $150M Stock Offering
Nursing

Oneview Healthcare Launches ‘Ovie’ Care Assistant to Ease Nursing Burden

Oneview Healthcare Launches ‘Ovie’ Care Assistant to Ease Nursing Burden Oneview Healthcare has launched Ovie, a groundbreaking GenAI product designed to offer personalized, real-time support for patients and their families during hospital stays. Oneview Healthcare has launched Ovie, a transformative…

Read MoreOneview Healthcare Launches ‘Ovie’ Care Assistant to Ease Nursing Burden

WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications

WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α)…

Read MoreWELIREG® (belzutifan) Gains First European Commission Approval for Two Indications